REVIEW ARTICLE
Year : 2021 | Volume
: 11 | Issue : 4 | Page : 348--351
Gene therapy for retinitis pigmentosa
Niloofar Piri, Jacob D Grodsky, Henry J Kaplan
Department of Ophthalmology, School of Medicine, Saint Louis University, St. Louis, MO, USA
Correspondence Address:
Dr. Niloofar Piri
1225 S Grand Blvd, Saint Louis, MO, 63104
USA
Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RP) is the most common cause of RP in North America. There is no proven cure for the disease, and multiple approaches are being studied. Gene therapy is an evolving field in medicine and ophthalmology. In this review, we will go over the basic concept of gene therapy and the different types of gene therapy that are currently being studied to treat this disease.
How to cite this article:
Piri N, Grodsky JD, Kaplan HJ. Gene therapy for retinitis pigmentosa.Taiwan J Ophthalmol 2021;11:348-351
|
How to cite this URL:
Piri N, Grodsky JD, Kaplan HJ. Gene therapy for retinitis pigmentosa. Taiwan J Ophthalmol [serial online] 2021 [cited 2022 Jan 22 ];11:348-351
Available from: https://www.e-tjo.org/article.asp?issn=2211-5056;year=2021;volume=11;issue=4;spage=348;epage=351;aulast=Piri;type=0 |
|
|
|
